HK Stock Market Move | Joinn Laboratories (06127) surged by more than 7% at the close. The potential of AI pharmaceuticals is being unleashed and is expected to empower the company's preclinical drug research.

Joinn Laboratories (06127) rose over 7% in the last session, as of the time of writing, up 6.7% to 14.98 Hong Kong dollars, with a turnover of 33.8677 million Hong Kong dollars. China Securities Co., Ltd. believes that the AI pharmaceutical field is undergoing rapid iteration and transformation, with the updating and iteration of algorithms and the support of computing power laying a good foundation for AI applications in the pharmaceutical field. Currently, AI algorithms have been deeply and profoundly applied in the preclinical drug discovery stage, and leading overseas clinical CRO companies have been deploying AI in clinical trials for many years. New drugs developed entirely by AI are expected to be successfully launched within 1-2 years. Haitong pointed out that in the field of non-clinical drug research, Joinn Laboratories has introduced a digital pathology-assisted analysis system, which enables the application of AI-assisted diagnosis for various organs in experimental animals, intelligent quality control of digital slices, and autonomous training of AI models. The application of AI-assisted diagnosis makes pathological diagnosis faster and more accurate. After analyzing the data with AI, there has been further improvement in efficiency in some areas.